Russell Tolander's questions to IMMUCELL CORP /DE/ (ICCC) leadership • Q1 2025
Question
Inquired about the impact of a past contamination event on prior-year EBITDA to set future expectations, the core business's EBITDA run rate, and requested an update on the Re-Tain product.
Answer
The impact of the last contamination event was primarily in early 2024, and the revenue rebound began in Q4 2024. The more recent 3-month and 6-month EBITDA figures are more representative of the current business run rate. For Re-Tain, the company is starting investigational use to gather market feedback while awaiting final FDA approval, which is held up by a contract manufacturer inspection.